Targeting accelerated progress at the IPAC-RS Nasal Innovation Forum 2025
Explore how Nanopharm presented strategies for accelerating patient-centric nasal product development at the IPAC-RS Nasal Innovation Forum 2025. Dive into key insights on regulatory science, advanced bioequivalence methods, and targeted drug delivery.
Aligning Alternative Bioequivilence with U.S. FDA: Advancing aerosol dose collection to enhance in vitro dissolution studies
Discover how Nanopharm’s DissoHale system advances aerosol dose collection and dissolution testing to support FDA-aligned alternative bioequivalence for OIDPs.
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
GDUFA: FDA adds further weight to modelling and simulation’s role in bioequivalence
GDUFA 2026: FDA strengthens role of modeling & simulation for inhaled generic drug bioequivalence. Learn how this shift enhances efficiency for OINDP development.
Optimizing OINDP Regulatory Paths With Model Master Files (MMF)
Streamline OINDP regulatory submissions with Model Master Files—confidential, reusable models that accelerate drug development and U.S. FDA review.
Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack
Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.
Nanopharm & FLUIDDA Interviews on SmartTrack: In Vitro-In Silico Approaches for Demonstrating Bioequivalence for OINDP
To support generic drug companies in obtaining a market license for their orally inhaled drug products (OIDPs), Nanopharm and FLUIDDA entered into an exclusive collaboration to combine Nanopharm’s SmartTrack™ with FLUIDDA’s Functional Respiratory Imaging technology to create a unique in-vitro in-silico platform. This allows pharma companies to shorten their clinical pathways – and potentially avoid […]
A Holistic Demonstration of SmartTrack™ and New Ways of Collaborating Combine for a Successful FDA Workshop
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Dual Excipient Integration in Dry Powder Inhaler Products
Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.
Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
